AXL inhibitors(AXL receptor tyrosine kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [11]

Active Indication

Neuroendocrine tumor of pancreasDifferentiated Thyroid Gland CarcinomaRenal Cell Carcinoma+ [189]

Inactive Indication

Advanced Bile Duct CarcinomaAdvanced breast cancerAdvanced Malignant Solid Neoplasm+ [45]

Originator Organization

Exelixis, Inc.

Active Organization

Exelixis, Inc.

National Cancer Institute

Ipsen SA

+ [14]

Inactive Organization

Jiangsu Hansoh Pharmaceutical Co., Ltd.

EMD Serono, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (29 Nov 2012),

Thyroid Cancer, Medullary

RegulationFast Track (United States), Orphan Drug (United States), Priority Review (United States), Breakthrough Therapy (United States)

Structure/Sequence

Molecular FormulaC32H30FN3O10

InChIKeyHFCFMRYTXDINDK-WNQIDUERSA-N

CAS Registry1140909-48-3

276

Clinical Trials associated with Cabozantinib (s)-Malate

NCT06900595

/ Not yet recruitingPhase 2IIT

A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with cemiplimab may kill more tumor cells in patients with locally advanced unresectable or recurrent/metastatic adrenocortical cancer.

Start Date13 Jun 2025

Sponsor / Collaborator

National Cancer Institute

NCT06811116

/ Not yet recruitingPhase 1/2IIT

A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-Catenin-Mutated Hepatocellular Carcinoma

This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contains a mutation (change) in the β-catenin gene. Sapanisertib and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sapanisertib and cabozantinib together may work better than giving cabozantinib alone in treating β-catenin-mutated metastatic hepatocellular carcinoma.

Start Date16 May 2025

Sponsor / Collaborator

National Cancer Institute

NCT06502171

/ Not yet recruitingPhase 1IIT

A Phase 1/1b/2 Study of Cabozantinib in Combination with Selumetinib for Plexiform Neurofibroma in Adults and Adolescents with Neurofibromatosis Type 1

Based on the clinical activity of both selumetinib and cabozantinib as monotherapies in clinical trials, the demonstrated activity of these agents in reduced doses in preclinical studies, and the non-overlapping toxicity profiles, the study will assess the tolerability and efficacy of selumetinib and cabozantinib in combination in participants with NF1 ≥16 years old with progressive and/or symptomatic PN in a phase 1/1b/2 clinical trial.
Trial Design Phase 1 This will be an open label, dose escalation phase. Dose level escalation will be determined by a rolling six design. In this design, up to 6 participants can be enrolled at a given dose level and then evaluated for dose limiting toxicity (DLT) within the DLT window. The DLT window is defined as 16 weeks in this study based on the long half-life of cabozantinib and the desire to have maximum confidence about long-term tolerability of the combination prior to proceeding to the next dose level.
Phase 1b Once the recommended phase 2 dose has been determined in phase 1, an expanded cohort of 12 participants will be enrolled in phase 1b portion of the study.
Phase 2 This will be an open label, single-arm phase using the recommended phase 2 dose.

Start Date01 Apr 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

[+2]

100 Clinical Results associated with Cabozantinib (s)-Malate

100 Translational Medicine associated with Cabozantinib (s)-Malate

100 Patents (Medical) associated with Cabozantinib (s)-Malate

2,627

Literatures (Medical) associated with Cabozantinib (s)-Malate

01 Apr 2025·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Optimization of immunotherapy-based combinations for metastatic renal cell carcinoma: A network meta-analysis

Review

Author: Rhie, Sandy Jeong ; Park, Sohyeon ; Park, Kalynn ; Kim, Chaeyoon

BACKGROUND:

Despite numerous meta-analyses comparing the efficacy and safety of immunotherapy-based combination therapies, the optimal therapeutic combinations remain unclear. This study aims to evaluate the optimal application of all immunotherapy-based combination therapy for advanced/metastatic renal cell carcinoma, focusing on efficacy and safety.

METHODS:

We systemically searched the Web of Science, Cochrane Library, and PubMed for studies regarding the first-line immunotherapy-based combination therapy in patients with advanced or metastatic renal cell carcinoma until April 15, 2024. We used network meta-analysis using a random effect model to facilitate direct and indirect treatment comparisons across outcomes.

RESULTS:

Seven clinical studies, including 5542 patients with metastatic renal cell carcinoma, were included in the network meta-analysis analysis. Regarding progression-free survival and overall survival, combined Toripalimab + Axitinib significantly outperformed other immunotherapy-based combination therapies. This regimen significantly improved progression-free survival in the intermediate/poor risk group when stratified by prognosis prediction risks compared to sunitinib alone. For the objective response rate, Avelumab + Axitinib was the most preferred strategy in the favorable-risk group, while Nivolumab + Cabozantinib was favored in the intermediate/poor-risk group compared to other immunotherapy-based combinations. The combinations of Nivolumab + Ipilimumab and Atezolizumab + Bevacizumab had favorable safety profiles.

CONCLUSIONS:

Immunotherapy-based combination therapies significantly improved progression-free survival, overall survival and objective response rate in patients with metastatic renal cell carcinoma compared to sunitinib monotherapy. However, careful monitoring and personalized treatment strategies are required to balance efficacy and safety in patients with underlying conditions. Future research should focus on optimizing treatment protocols and elucidating the mechanisms of adverse events.

01 Apr 2025·BIOCHIMIE

Combination of chemotherapy and c-MET inhibitors has synergistic effects in c-MET overexpressing pancreatic cancer cells

Article

Author: Firuzi, Omidreza ; Firoozi, Roya ; Tavakkoli, Marjan ; Nazari, Somayeh ; Alipour, Alireza ; Moosavi, Fatemeh

Pancreatic ductal adenocarcinoma (PDAC) remains as one of the most lethal malignancies. c-MET is an important oncogenic kinase involved in PDAC progression. We determined the anticancer effect of c-MET inhibitors, crizotinib and cabozantinib, combined with chemotherapeutic agents, doxorubicin, oxaliplatin and gemcitabine, against different PDAC and a lung adenocarcinoma cell line expressing different levels of c-MET. MTT assay was performed to assess cell growth inhibition. Synergistic combinations were evaluated in spheroid cultures, while apoptosis was determined through Hoechst33258 staining. The effect of drug combinations on cell cycle and apoptosis induction was examined by RNase/PI flow cytometric assay. We also evaluated reactive oxygen species (ROS) levels using 2',7'-dichlorofluorescein-diacetate (DCFH-DA) assay to explore the possible mechanisms contributing to synergism. Combination of crizotinib or cabozantinib with doxorubicin exhibited synergistic effects in c-MET overexpressing cells. Conversely, combinations of c-MET inhibitors with other agents were additive or even antagonistic. Combination index (CI) values calculated with Calcusyn software were 0.631-0.730 for crizotinib and 0.542-0.746 for cabozantinib co-administered with doxorubicin. These synergistic combinations showed significant spheroid growth inhibition and apoptosis induction in Suit-2, c-MET dependent PDAC cells. These combinations also significantly increased the number of cells in both apoptotic sub-G1 phase and the G2/M phase compared to single-drug treatment. Increased ROS production seemed to be a possible mechanism underlying synergism. In conclusion, c-MET inhibitors synergize with DNA damaging agent, doxorubicin, in cancer cells with c-MET overexpression, indicating that these combination therapies may be a promising cancer therapeutic strategy.

01 Apr 2025·MOLECULAR DIVERSITY

Targeting AFP-RARβ complex formation: a potential strategy for treating AFP-positive hepatocellular carcinoma

Article

Author: Dev, Radul R ; Soman, Sowmya ; Banjan, Bhavya ; Raju, Rajesh ; Vishwakarma, Riya ; Rehman, Niyas ; Kalath, Haritha ; Kumar, Pankaj ; Revikumar, Amjesh ; Abhinand, Chandran S ; Ramakrishnan, Krishnapriya

Alpha-fetoprotein (AFP) is a glycoprotein primarily expressed during embryogenesis, with declining levels postnatally. Elevated AFP levels correlate with pathological conditions such as liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Recent investigations underscore AFP's intracellular role in HCC progression, wherein it forms complexes with proteins like Phosphatase and tensin homolog (PTEN), Caspase 3 (CASP3), and Retinoic acid receptors and Retinoid X receptors (RAR/RXR). RAR and RXR regulate gene expression linked to cell death and tumorigenesis in normal physiology. AFP impedes RAR/RXR dimerization, nuclear translocation, and function, promoting gene expression favoring cancer progression in HCC that provoked us to target AFP as a drug candidate. Despite extensive studies, inhibitors targeting AFP to disrupt complex formation and activities remain scarce. In this study, employing protein-protein docking, amino acid residues involved in AFP-RARβ interaction were identified, guiding the definition of AFP's active site for potential inhibitor screening. Currently, kinase inhibitors play a significant role in cancer treatment and, the present study explores the potential of repurposing FDA-approved protein kinase inhibitors to target AFP. Molecular docking with kinase inhibitors revealed Lapatinib as a candidate drug of the AFP-RARβ complex. Molecular dynamics simulations and binding energy calculations, employing Mechanic/Poisson-Boltzmann Surface Area (MM-PBSA), confirmed Lapatinib's stability with AFP. The study suggests Lapatinib's potential in disrupting the AFP-RARβ complex, providing a promising avenue for treating molecularly stratified AFP-positive HCC or its early stages.

452

News (Medical) associated with Cabozantinib (s)-Malate

26 Mar 2025

·www.fiercepharma.com

To approve Exelixis' Cabometyx in neuroendocrine tumors, FDA recognizes 'crossover impact' on survival

Exelixis might soon have to test the FDA’s tolerance of a lackluster overall survival showing again for Cabometyx in prostate cancer. After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors.The small-molecule drug is now allowed for patients 12 years of age and older with previously treated, advanced, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors (pNET or epNET), the FDA said Wednesday.In an interesting and unusual item in Cabometyx’s updated label, the FDA acknowledges the potential impact that control arm patient crossovers may have had on Cabometyx’s patient survival results in a phase 3 trial.The approval could be an encouraging sign for oncology drug developers because, as the likes of Novartis know too well, the FDA has not been very receptive to companies using patient crossovers to justify a signal that may hint at a potential detriment to patient survival. Even though it doesn’t mean just any company with a crossover trial design can now expect to win over the FDA, Cabometyx serves as living proof that the agency is open to that line of reasoning.In Cabometyx’s case specifically, during an updated overall survival analysis of the phase 3 Cabinet trial that Exelixis used to support its NET bid, overall survival data favored placebo in both pNET and epNET patients.The overall survival data, which were immature, tallied 48% deaths in Cabometyx arm and 52% deaths in the placebo arm, but a preliminary 1% increased risk of death for the tyrosine kinase inhibitor in pNET patients. The numbers were 63% deaths for Cabometyx and 60% for placebo in epNET patients, resulting in a 5% higher risk of death for the active drug.The lackluster overall survival data came in stark contrast with the massive 78% and 60% progression-free survival improvements that Cabometyx has shown in the two patient subgroups, respectively. Sometimes such a disconnect between a major tumor progression benefit and muted overall survival showing could be attributed to nasty side effects harming the patients’ overall wellbeing. But in the Cabinet trial case, investigators and Exelixis have pointed to a high rate of patients in the control arm who crossed over to receive Cabometyx later upon disease progression. As the FDA label shows, 52% of pNET patients and 37% epNET participants in the control group got open-label Cabometyx, “which may impact the OS endpoint.”When the FDA unveiled a meeting of external experts to discuss Exelixis’ NET application, analysts suspected that the agency had questions about the survival data. The FDA then canceled the gathering in January.The medical community has been raving about Cabometyx in a hard-to-treat tumor type, in which patients face poor prognosis. In January, the National Comprehensive Cancer Network updated its guidelines to recommend Cabometyx as a category 1—the highest—preferred regimen for the majority of previously treated well-differentiated advanced NET, plus a category 2A backing for other forms of advanced NET.The current FDA approval is limited to well-differentiated NET even though the phase 3 Cabinet trial enrolled a small number of patients with moderately-differentiated cancers. In a Wednesday, March 26 press release, Exelixis noted that an estimated 161,000 to 192,000 people are living with unresectable, advanced NET, but the company didn’t break down how many are well-differentiated cases.NET can develop in any part of the body, but those that start in the gastrointestinal tract or in the lungs are the most common, while pNET can be more aggressive. By William Blair’s estimate, the entire NET market is expected to reach $4.6 billion by 2030.Also in NET, Exelixis is preparing to start a pivotal trial coded Stellar-311 to evaluate its investigational zanalintinib, a next-generation asset, versus Novartis’ Afinitor. Exelixis has high hopes for zanalintinib, having put its 2033 U.S. sales potential at $5 billion. With the NET nod in the pocket, Exelixis might soon have to test the FDA’s tolerance of a lackluster overall survival showing again. A combination of Cabometyx and Roche’s Tecentriq previously failed to deliver a statistically significant overall survival benefit compared with a change of novel hormonal therapy in metastatic castration-resistant prostate cancer in the final analysis of the Contact-02 trial. The study did meet its other dual primary endpoint, progression-free survival.Exelixis has said it intends to file an application with the FDA but has not done so. During a recent investors’ call, Exelixis management said the company will turn to the prostate cancer indication after it gets NET across the finish line.In response to a Fierce Pharma inquiry Wednesday, an Exelixis spokesperson said the company will provide an update on its regulatory plans at an appropriate time.

Phase 3Clinical ResultDrug ApprovalAccelerated ApprovalClinical Trial Termination

26 Mar 2025

·endpts.com

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors

The FDA has approved Exelixis’ cancer drug Cabometyx to treat advanced neuroendocrine tumors inside and outside of the pancreas, marking two new indications for the company’s primary source of revenue. The new label includes adults and children 12 years and older with previously treated, locally advanced or metastatic tumors that can’t be removed with surgery. The cancer treatment was already approved to treat renal cell carcinoma, hepatocellular carcinoma and thyroid cancer. The approval, announced Wednesday, was based on a double-blind, placebo-controlled study with two separate cohorts for patients with tumors inside and outside of the pancreas, respectively. In the cohort of patients with tumors inside the pancreas, Cabometyx-treated participants notched a median progression-free survival of 13.8 months, compared to 3.3 months for patients given placebo. The overall response rate was 18% and 0%, respectively. In the other cohort, which included 100 additional patients, median PFS was 8.5 months in the treatment arm compared to 4.2 months for placebo. The overall response rate was 5% for patients given Cabometyx. Overall survival data weren’t mature for either cohort. Exelixis and the FDA said that the safety profile was consistent with Cabometyx in other cancer types, though the rate of hypertension, regardless of treatment arm, was higher in patients with neuroendocrine tumors compared to the other cancers that the drug is approved to treat. The company also said that “a majority of patients treated with Cabometyx required dose modifications or reductions to manage adverse events.” The additional indications add fuel to Exelixis’ core revenue engine, after global revenue for the cabozantinib franchise, which Cabometyx is the foundation of, exceeded $2.5 billion in 2024. Further growing the franchise was the core argument of activist investors at Farallon Capital Management, who rebuilt the board almost two years ago. More treatments for patients with neuroendocrine tumors are in the works. Amy Peterson, Exelixis’ chief medical officer and EVP of product development and medical affairs, reaffirmed in a statement the company’s plans to launch a study of its clinical-stage zanzalintinib compared to everolimus in the first half of this year.

Clinical ResultDrug ApprovalASCOAccelerated Approval

26 Mar 2025

·www.globenewswire.com

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that an abstract containing preclinical data for KO-2806, the Company’s next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib, a tyrosine kinase inhibitor (TKI), in clear cell renal cell carcinoma (ccRCC), has been accepted for an oral presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL on April 29, 2025. “The latest findings for our next-generation farnesyl transferase inhibitor, KO-2806, being presented at this year’s AACR Annual Meeting, add to the growing body of data demonstrating the potential of FTIs as companion therapeutic agents to augment the antitumor activities of various targeted therapies and to overcome resistance in combination,” said Francis Burrows, Ph.D., Chief Scientific Officer of Kura Oncology. “We continue to make good progress in our FIT-001 trial evaluating KO-2806 in solid tumor indications where there is unmet medical need, and we look forward to presenting the first clinical data for KO-2806 as monotherapy and in combination with cabozantinib for the treatment of RCC later this year.” The title and session information for the oral presentation are listed below. Full abstract details including title and text are currently available to registrants via the AACR online itinerary planner. Details of the oral presentation, entitled “Farnesyl transferase inhibitor KO-2806 enhances the antitumor activity of cabozantinib in ccRCC tumors that progress on anti-VEGFR agents” (oral 6370), are as follows: Session Date and Time: Monday, April 28, 2025; 2:30 PM - 4:45 PM CTSession Title: Minisymposium Novel Antitumor AgentsPresentation Time: 4:25 PM - 4:40 PM CT A copy of the presentation will be available in the Posters and Presentations section on Kura’s website at the beginning of the presentation session. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and the companies anticipate submission of a New Drug Application (NDA) to the FDA in the second quarter of 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent HNSCC. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the potential of FTIs to augment the antitumor activities of targeted therapies and to overcome resistance; the progress of Kura’s clinical trials; the efficacy, safety and therapeutic potential of Kura’s product candidates, ziftomenib, KO-2806 and tipifarnib; the expected timing and presentation of results and data from clinical trials; and the anticipated timing of submission of an NDA for ziftomenib. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investors:Patti BankManaging Director(415) 513-1284patti.bank@icrhealthcare.com Media:Alexandra WeingartenAssociate Director, Corporate Communications(858) 500-8822alexandra@kuraoncology.com

Phase 1License out/inAACRBreakthrough TherapyPhase 2

100 Deals associated with Cabozantinib (s)-Malate

External Link

KEGG	Wiki	ATC	Drug Bank
D10095	Cabozantinib (s)-Malate	L01XE26	DB08875

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neuroendocrine tumor of pancreas	United States	Exelixis, Inc.	26 Mar 2025
Differentiated Thyroid Gland Carcinoma	South Korea	Ipsen Ltd.	26 Sep 2017
Renal Cell Carcinoma	South Korea	Ipsen Ltd.	26 Sep 2017
Hepatocellular Carcinoma	European Union	Ipsen Pharma SAS	09 Sep 2016
Hepatocellular Carcinoma	Iceland	Ipsen Pharma SAS	09 Sep 2016
Hepatocellular Carcinoma	Liechtenstein	Ipsen Pharma SAS	09 Sep 2016
Hepatocellular Carcinoma	Norway	Ipsen Pharma SAS	09 Sep 2016
Advanced Renal Cell Carcinoma	United States	Exelixis, Inc.	25 Apr 2016
Thyroid Cancer, Medullary	United States	Exelixis, Inc.	29 Nov 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	NDA/BLA	China	Jiangsu Hansoh Pharmaceutical Co., Ltd.	28 Sep 2020
Refractory Differentiated Thyroid Gland Carcinoma	Phase 3	United States	National Cancer Institute	22 Aug 2024
Metastatic osteosarcoma	Phase 3	-	National Cancer Institute	13 Jan 2023
Unresectable Bone Sarcoma	Phase 3	-	National Cancer Institute	13 Jan 2023
Advanced Urothelial Carcinoma	Phase 3	United States	National Cancer Institute	03 Jun 2022
Advanced Urothelial Carcinoma	Phase 3	Canada	National Cancer Institute	03 Jun 2022
Bladder Cancer	Phase 3	United States	National Cancer Institute	03 Jun 2022
Bladder Cancer	Phase 3	Canada	National Cancer Institute	03 Jun 2022
Metastatic Urethral Urothelial Carcinoma	Phase 3	United States	National Cancer Institute	03 Jun 2022
Metastatic Urethral Urothelial Carcinoma	Phase 3	Canada	National Cancer Institute	03 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06026410 (FIT-001, AACR2025)	Phase 1	-	-	Farnesyl transferase inhibitor KO-2806	fiwwsviegr(vzjpblzkgr) = zvmvkkzvfx hssiybjhip (bihlqpupyr )	Positive	28 Apr 2025
				Cabozantinib	ixjuyljrrm(qlorchwapc) = mdjvpqvhpq pewancnsae (vurpqyaigb )
NCT03468218 (CTgov)	Phase 2	Squamous cell carcinoma of the paranasal sinus \| Squamous cell carcinoma of the oral cavity recurrent \| Squamous Cell Carcinoma of the Oropharynx ... View more	36	Cabozantinib+pembrolizumab	ekdlqkicem = aechtgoppo kstpikulqm (iktufyxyku, edknfwjvnj - vkwchbdpvi) View more	-	25 Mar 2025
NCT03945773 (CaboPoint, CTgov)	Phase 2	Metastatic Renal Cell Carcinoma \| Locally Advanced Renal Cell Carcinoma \| Metastatic Clear Cell Renal Cell Carcinoma	127	Cabozantinib (Cohort A)	xstbblkvdu = lcpdifkhir aaiogesroi (bwgzqolxik, byhiknhilm - wrhpfnlgur) View more	-	25 Mar 2025
				Cabozantinib (Cohort B)	syrtrbvskx(kvphiwrtdw) = wcjjlefagl mizgsjhusl (hfbkyynrcu, onaweugoml - ztgkdtfrsn) View more
NCT04197310 (CTgov)	Phase 2	Carcinoid Tumor \| Gastrointestinal Neoplasms	19	Nivolumab+Cabozantinib	gqgujunjsb = fyrbfgzzfo epdhinipba (upfpdpytkp, xdgkeemsrn - wreiwwxkqr) View more	-	25 Mar 2025
NCT03170960 (COSMIC-021, Pubmed \| J Clin Oncol)	Phase 1	Metastatic urothelial carcinoma First line \| First line	121	Cabozantinib 40 mg + Atezolizumab 1,200 mg	xeapfvphps(ihwnsbtjhi) = amrwosysna ptqkvwaran (emctndkryl, 15 - 49) View more	Positive	18 Feb 2025
METEOR (ASCO_GU2025) Manual	Not Applicable	Metastatic Renal Cell Carcinoma Second line	603	Cabozantinibipilimumabnivolumab (1L ipilimumab/nivolumab)	qvowzxpvyr(hipajcnhde) = cshbosxxbh ivgmfikgju (obcmqvcgeo ) View more	Positive	13 Feb 2025
				Cabozantinib (1L anti-PD1 + TKI)	qvowzxpvyr(hipajcnhde) = bnniovbsks ivgmfikgju (obcmqvcgeo ) View more
JPRN-jRCTs031210220 (ASCO_GU2025) Manual	Phase 2	Advanced Renal Cell Carcinoma	31	Cabozantinib 60 mg	mmzyrneitd(syiruuefqg) = zubwcyuoea mnzlxuhmxt (mafcoyvxqj, 1.2 - 18.9) View more	Positive	13 Feb 2025
NCT03141177 (CheckMate 9ER, ASCO_GU2025) Manual	Phase 3	Advanced Renal Cell Carcinoma First line	651	Nivolumab 240 mg + Cabozantinib 40 mg	johhnqensl(tfornklcde) = gqmwymyuwt vyrponbuwb (cwdgdvctjc, 12.5 - 19.3) View more	Positive	13 Feb 2025
				Sunitinib 50 mg	johhnqensl(tfornklcde) = xrmqfbagvc vyrponbuwb (cwdgdvctjc, 7.0 - 9.7) View more
NCT04714697 (AT ASIA, KCSG GU21-02, ASCO_GU2025) Manual	Phase 2	Renal Cell Carcinoma Second line	88	Cabozantinib	aismqntaud(cabgbrywwq) = zgjoedkrzc rjrkjcrcuz (hfutytiady ) View more	Positive	13 Feb 2025
				Cabozantinib (first-line nivolumab plus ipilimumab)	rsewwekcyi(audfqybfjb) = cjfpvvldnc bkejpowpkr (fvugxmmuvn, 40.1–61.5) View more
NCT03634540 (LITESPARK-003, ASCO_GU2025) Manual	Phase 2	Renal Cell Carcinoma	102	Belzutifan 120 mg + Cabozantinib 60 mg (patients with no prior systemic therapy)	vvxqjcayxb(lkuwtuiwfy) = kuqqldnulp sjzbtzdbgx (fgpmzjmjdk, 55 - 82) View more	Positive	13 Feb 2025
				Belzutifan 120 mgBelzutifan 120 mg + CabozantinibCabozantinib 60 mg (patients who had received prior immunotherapy and ≤2 systemic regimens)	vvxqjcayxb(lkuwtuiwfy) = dknxlibzoc sjzbtzdbgx (fgpmzjmjdk, 19 - 45) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis